文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

亚太肝病学会代谢相关性脂肪性肝病临床诊疗指南。

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

机构信息

Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead, NSW, 2145, Australia.

Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.

出版信息

Hepatol Int. 2020 Dec;14(6):889-919. doi: 10.1007/s12072-020-10094-2. Epub 2020 Oct 1.


DOI:10.1007/s12072-020-10094-2
PMID:33006093
Abstract

Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver disease and affects nearly a quarter of the global population. The objective of this work was to present the clinical practice guidelines of the Asian Pacific Association for the Study of the Liver (APASL) on MAFLD. The guidelines cover various aspects of MAFLD including its epidemiology, diagnosis, screening, assessment, and treatment. The document is intended for practical use and for setting the stage for advancing clinical practice, knowledge, and research of MAFLD in adults, with specific reference to special groups as necessary. The guidelines also seek to improve patient care and awareness of the disease and assist stakeholders in the decision-making process by providing evidence-based data. The guidelines take into consideration the burden of clinical management for the healthcare sector.

摘要

代谢相关性脂肪性肝病(MAFLD)是全球范围内导致肝脏疾病的主要原因,影响了近全球四分之一的人口。本项工作旨在介绍亚太肝病学会(APASL)关于 MAFLD 的临床实践指南。该指南涵盖了 MAFLD 的多个方面,包括其流行病学、诊断、筛查、评估和治疗。该文件旨在实际应用,并为推进成人 MAFLD 的临床实践、知识和研究奠定基础,必要时还特别针对特殊人群。该指南还旨在通过提供基于证据的数据来改善患者对该疾病的认识和护理,并协助利益相关者在决策过程中的工作。该指南考虑到了医疗保健部门临床管理的负担。

相似文献

[1]
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Hepatol Int. 2020-12

[2]
The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Saudi J Gastroenterol. 2022

[3]
MAFLD, patient-centred care, and APASL.

Hepatol Int. 2022-10

[4]
Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines.

J Gastroenterol Hepatol. 2007-6

[5]
From NAFLD in clinical practice to answers from guidelines.

J Hepatol. 2013-6-7

[6]
Metabolic dysfunction associated fatty liver disease (MAFLD) and serum vitamin D concentration in South Korea.

Asia Pac J Clin Nutr. 2022

[7]
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.

Clin Mol Hepatol. 2022-4

[8]
A Review of the Increasing Prevalence of Metabolic-Associated Fatty Liver Disease (MAFLD) in Children and Adolescents Worldwide and in Mexico and the Implications for Public Health.

Med Sci Monit. 2021-8-30

[9]
Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update.

Nutrients. 2020-10-28

[10]
How should we manage patients with non-alcoholic fatty liver disease in 2007?

J Gastroenterol Hepatol. 2007-6

引用本文的文献

[1]
Genetic Risk of MASLD in Mongolians: Role of and SNPs.

Curr Issues Mol Biol. 2025-8-1

[2]
Trends in the prevalence of steatotic liver disease among Chinese adults, 2015-2023: A nationwide cross-sectional study.

Hepatol Commun. 2025-8-26

[3]
HOMA-IR, an independent predictor of advanced liver fibrosis in metabolic-dysfunction associated fatty liver disease: a cross-sectional study in Egyptian patients.

Sci Rep. 2025-8-24

[4]
Clinical efficacy of 308 nm excimer laser irradiation combined with 0.1% tacrolimus ointment in the treatment of plaque-type psoriasis.

Lasers Med Sci. 2025-8-22

[5]
The Rising Burden of Fatty Liver Disease in the Middle East: Why Oman Must Act Now?

Oman Med J. 2025-1-31

[6]
Outcomes of empagliflozin in nondiabetic fatty liver patients: A randomized controlled trial.

J Taibah Univ Med Sci. 2025-8-7

[7]
Risk factor analysis and nomogram development for advanced-stage hepatic fibrosis in patients with Wilson's disease.

Front Med (Lausanne). 2025-7-30

[8]
Unrecognised rural-urban disparities in epidemiology of metabolic-associated fatty liver disease in the representative area of China.

BMJ Nutr Prev Health. 2025-5-7

[9]
Are we standing on the shifting sands of post-transplant metabolic-associated steatotic liver disease?

World J Hepatol. 2025-7-27

[10]
Development of a novel deep learning method that transforms tabular input variables into images for the prediction of SLD.

Sci Rep. 2025-7-31

本文引用的文献

[1]
Expansion of dysfunctional CD56-CD16+ NK cells in chronic hepatitis B patients.

Liver Int. 2021-5

[2]
Farnesoid X Receptor Activation Impairs Liver Progenitor Cell-Mediated Liver Regeneration via the PTEN-PI3K-AKT-mTOR Axis in Zebrafish.

Hepatology. 2021-7

[3]
Incidence rates, risk factors, and outcomes of aspiration pneumonia after gastric endoscopic submucosal dissection: A systematic review and meta-analysis.

J Gastroenterol Hepatol. 2021-6

[4]
The NAFLD-MAFLD debate: Eminence vs evidence.

Liver Int. 2021-2

[5]
Association Between Preadmission Acid Suppressive Medication Exposure and Severity of Illness in Patients Hospitalized With COVID-19.

Gastroenterology. 2021-3

[6]
Artificial intelligence-enabled screening for diabetic retinopathy: a real-world, multicenter and prospective study.

BMJ Open Diabetes Res Care. 2020-10

[7]
Reply to: correspondence regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement": Bringing evidence to the NAFLD-MAFLD debate.

J Hepatol. 2020-12

[8]
Gastroduodenal tuberculosis: a case series and a management focused systematic review.

Expert Rev Gastroenterol Hepatol. 2021-1

[9]
Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis.

Liver Int. 2020-11

[10]
Enhanced Liver Fibrosis Score Can Be Used to Predict Liver-Related Events in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis.

Clin Gastroenterol Hepatol. 2021-6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索